A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: a large, multicentre, observational study by Bühler, Klaus & Naether, Olaf
INFERTILITY
A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice:
a large, multicentre, observational study
KLAUS BU ¨ HLER
1 & OLAF NAETHER
2
1Centre for Reproductive Medicine and Gynaecological Endocrinology, Langenhagen, Germany and
2Fertility Center Hamburg,
Hamburg, Germany
(Accepted 23 June 2010)
Abstract
Background. A 2:1 (150 IU:75 IU) follitropin alfa:lutropin alfa formulation has been developed. A 3-year post-marketing
surveillance study is ongoing in Germany to explore the use of this formulation in routine clinical practice.
Materials and methods. An 11-month interim analysis of data from assisted reproductive technology (ART) cycles only is
described.
Results. Data were available from 857 patients undergoing 919 cycles of ART at 19 centres. Most patients (58.7%) were aged
 35 years, and many (41.3%) were undergoing their ﬁrst ART cycle. Main reasons cited by physicians for prescribing this
formulation were poor response in a previous treatment cycle (n¼303) and low basal luteinizing hormone (LH) level (n¼107).
Mean (standard deviation) duration of ovarian stimulation was 10.8 (2.6) days. In 90.7% of cycles, the 2:1 formulation was
administered throughout the stimulation period. Most frequent LH daily dose was 75 IU. Embryo transfer was conducted in 741
cycles; clinical pregnancy rate per transfer was 27.5%. Three cases of ovarian hyperstimulation syndrome developed in three
patients (3/741 [0.4%] cycles); one required hospitalization. No other major safety events were reported.
Conclusion. This interim analysis shows that use of the 2:1 formulation for ovarian stimulation during routine ART
procedures is effective in achieving clinical pregnancies and is associated with a positive safety proﬁle.
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Introduction
Folliclestimulating hormone (FSH) and luteinizing hormone
(LH) are essential for the development of ovarian follicles and
subsequent stages of maturation and ovulation [1]. Severely
reduced hypothalamic or pituitary activity results in LH and
FSH deﬁciency (WHO Group I anovulatory infertility;
hypogonadotrophic hypogonadism [HH]). Administration
of exogenous FSH in combination with LH has proven to be
effective in promoting follicular maturation, ovulation and
pregnancy in women with HH [2–5]. Both FSH and LH are
commercially available as urinary-derived or recombinant
hormones. Unlike urinary-derived hormones, recombinant
formulations provide a pure and consistent source of
gonadotrophins [6].
A 2:1 formulation of recombinant human (r-h)FSH and
r-hLH (in a ﬁxed-dose combination of 150 IU r-hFSH
[follitropin alfa]:75 IU r-hLH [lutropin alfa]) has been
developed. In the combined formulation, there are no
pharmacokineticorpharmacodynamicinteractionsbetween
the constituent gonadotrophins, and their bioactivity is
unaltered [7–10], thus, allowing the administration of
both hormones in a single injection. By avoiding the need
for two separate injections or mixing of gonadotrophins
prior to injection, the 2:1 formulation of follitropin alfa
and lutropin alfa offers potential beneﬁts for patient
convenience.
Although the majority of normogonadotrophic women
have adequate endogenous LH levels, certain patient
subgroups may beneﬁt from LH supplementation during
assisted reproductive technology (ART) [11,12]. Accord-
ingly, physicians have attempted to exploit the potential
beneﬁtsofthe2:1formulationoffollitropinalfaandlutropin
alfa in a variety of patient populations.
The 2:1 formulation of follitropin alfa and lutropin alfa has
been available in Germany since October 2007 for the
stimulation of follicular development in women with severe
FSH and LH deﬁciency (deﬁned in clinical trials by an
endogenous serum LH level of 51.2 IU/l) [3,13]. A 3-year
post-marketing surveillance study is in progress in Germany
toexploretheuseofthe2:1formulationoffollitropinalfaand
lutropin alfa in routine clinical practice. The study aims to
deﬁne the characteristics of patients with LH deﬁciency in
daily practice and learn about the ovarian stimulation proto-
cols that such patients undergo. Here, we present an interim
analysis of data on ART cycles collected after 11 months.
Methods
Study design
An observational, post-marketing surveillance study was
initiated across in vitro fertilisation (IVF) centres in
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patients at 49 centres between January 2008 and December
2010. An interim analysis was performed on data collected
between January and November 2008 from ART cycles
only.
Assessments
Routine clinical data for patients undergoing cycles of
conventional IVF or intracytoplasmic sperm injection
(ICSI) were entered prospectively into an electronic
database system (RecDate [14]). Data from more than
one cycle per patient were permitted.
A questionnaire prior to initiation of treatment with the
2:1 formulation of follitropin alfa and lutropin alfa (Merck
Serono S.A. – Geneva, Switzerland, an afﬁliate of Merck
KGaA, Darmstadt, Germany) was completed by the
clinician of each individual patient. One or more of the
following reasons for prescribing the therapy could be
selected: low serum LH level, low serum oestrogen level,
thin endometrium, amenorrhoea, or ‘other’. If ‘other’ was
selected, the clinician was prompted to specify the
reason(s) using a free text box.
Statistical analysis
Endpoints included the prescribed dose and duration of
treatment with the 2:1 formulation of follitropin alfa and
lutropin alfa.
In accordance with the design and objective of the study,
statistical evaluation focussed on a summary and detailed
report of the data obtained by means of descriptive
statistics (means, standard deviations [SD], frequencies,
percentages). No statistical hypotheses were pre-speciﬁed,
and no statistical tests were performed.
Results
Patient characteristics
At the time of this analysis, data were available from 19
German IVF centres. In total, 857 patients had undergone
919 cycles of ART using the 2:1 formulation of follitropin
alfa and lutropin alfa. ICSI and IVF were performed in
73% and 23% of cycles, respectively.
Baseline demographic and clinical characteristics of the
patients are shown in Table I. The majority of the study
population (58.7%) were aged  35 years (range: 19.0–48.0
years). The number of previous ART cycles undertaken by
the 857 patients is shown in Table II; this was the ﬁrst ART
cycle for just over 40% of patients.
Reasons for prescribing the 2:1 formulation of follitropin alfa
and lutropin alfa
The main reasons cited by clinicians for prescribing the
2:1 formulation of follitropin alfa and lutropin alfa are
shown in Figure 1. Low serum LH level was cited as the
reason for prescribing the 2:1 formulation of follitropin alfa
and lutropin alfa in 107 patients (Figure 1a). The most
common ‘other’ reason cited for prescribing the 2:1
Table I. Baseline patient characteristics.
Variable
Number of
patients
analysed Mean (SD)
Age, years 838 34.8 (4.5)
BMI, kg/m
2 848 23.1 (3.7)
Serum LH level, IU/l 743 5.5 (8.5)
Serum FSH level, IU/l 421 11.3 (13.0)
Serum oestradiol level, pg/ml 721 37.4 (36.0)
AFC (number of follicles 511 mm) 279 6.7 (3.7)
AFC, antral follicle count; BMI, body mass index; FSH, follicle-
stimulating hormone; LH, luteinizing hormone; SD, standard
deviation.
Table II. Assisted reproductive technology cycle history.
Number of previous ART cycles Patients n (%)
0 354 (41.3)
1 200 (23.3)
2 143 (16.7)
 3 160 (18.7)
Total number of patients analysed¼857.
Figure 1. Most common reasons cited by clinicians for prescribing
the 2:1 formulation of follitropin alfa and lutropin alfa. (a) The
number of patients who were prescribed the 2:1 formulation of
follitropin alfa and lutropin alfa for one (or more) of the pre-
speciﬁed reasons. (b) The number of patients who were prescribed
the 2:1 formulation of follitropin alfa and lutropin alfa for ‘other’
reasons (the seven reasons most frequently cited by clinicians are
shown). ART, assisted reproductive technology; LH, luteinizing
hormone; PCOS, polycystic ovarian syndrome.
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a previous poor response in ART cycles (303 patients;
Figure 1b).
Interventions
The proportions of patients who received various drug
treatments are shown in Table III. Approximately twice as
many cycles involved the use of gonadotrophin-releasing
hormone (GnRH) agonists as antagonists for pituitary
suppression. Most (95.5%) of the GnRH-agonist cycles
were performed using a long protocol.
The mean (SD) duration of ovarian stimulation was 10.8
(2.6) days. The mean (SD) total dose of r-hFSH and
r-hLH received per cycle was 2644.4 (1178.3) IU and
1185.5 (572.1) IU, respectively.
Of the 919 cycles documented, information relating to
the dose of the 2:1 formulation of follitropin alfa and
lutropin alfa was available for 654 cycles. In 593 (90.7% of
cycles analysed) cycles, the 2:1 formulation of follitropin
alfa and lutropin alfa was administered throughout ovarian
stimulation. Of these, a consistent daily dose of 75 IU LH
was received in 351 (59.2%) cycles, a consistent daily dose
of 150 IU LH was received in 171 (28.8%) cycles and a
consistent daily dose of 225 IU LH was received in 23
(3.9%) of cycles. A dose adjustment of the 2:1 formulation
of follitropin alfa and lutropin alfa was made during the
stimulation period in the remaining cycles: the dose was
simply altered in 41 (6.9%) cycles, whereas in 7 (1.2%)
cycles additional r-hFSH was given and consequently the
FSH:LH ratio was greater than 2:1.
Effectiveness and safety data
Of the 919 cycles documented, human chorionic gonado-
trophin was administered as scheduled in 877 (95.4%)
cycles, oocyte pick-up was performed in 858 (93.4%)
cycles and insemination via IVF or ICSI was achieved in
831 (90.4%) cycles. Fresh embryo transfer was conducted
in 741 (89.2%) of these cycles.
The mean (SD) number of oocytes retrieved per patient
was 8.6 (5.6), of which a mean number of 6.8 (79.5%) were
mature oocytes. A total of 62.5% of inseminated/injected
oocytes were fertilized and developed to the two pronuclear
(2PN) stage of development (mean [SD] of 4.1 [3.1] 2PN
oocytes per patient).
The number of embryos transferred is shown in
Table IV. The mean (SD) number of embryos transferred
per cycle was 2.02 (0.61). The implantation rate per
embryo transferred was 15.9% (238/1499). Clinical preg-
nancy was achieved after approximately one quarter of
embryo transfer procedures (204/741, 27.5%). Daily doses
of 150 IU r-hFSH:75 IU r-hLH and 300 IU r-hFSH:150
IU r-hLH resulted in clinical pregnancy rates per embryo
transfer of 32.1% and 16.3%, respectively.
A total of 204 pregnancies were recorded, and informa-
tion was available on the outcome of 106 pregnancies. In
total, 78 babies were born from 60 pregnancies: 43
singleton and 17 multiple deliveries (16 pairs of twins
and 1 set of triplets). Five babies had congenital
abnormalities (three singleton and two multiple births)
and eight required admission to neonatal intensive care
(two singletons and six from multiple births). There were
41 spontaneous miscarriages and ﬁve ectopic pregnancies.
Three cases of ovarian hyperstimulation syndrome
(OHSS) were reported in three patients (3/741 [0.4%]
cycles that resulted in embryo transfer). Two of the cases of
OHSS were considered severe (Grade III OHSS) but did
not require hospitalization. One case of OHSS (that
occurred in a cycle in which pregnancy was achieved)
required hospitalization. The 34-year-old patient, who had
hyperprolactinaemia, underwent ovarian stimulation for 9
days with a total dose of 2550:1275 IU of r-hFSH:r-hLH.
She subsequently made a full recovery from OHSS. No
other safety events were reported in this observational
study.
Discussion
There is little available data on the use of LH supplementa-
tion in ART clinical practice with respect to the most
suitable treatment protocol, the optimal timing of LH
administration, or the most appropriate dose of LH. This
3-year post-marketing surveillance study will explore the
potential role of LH, and evaluate use of the 2:1
formulation of follitropin alfa and lutropin alfa, in routine
clinical practice.
A total of 857 patients undergoing 919 cycles of ART
were included in this interim analysis. Of these, a low
serum LH level at baseline was the reason cited for
prescribing the 2:1 formulation of follitropin alfa and
lutropin alfa for 107 patients. However, the most com-
monly cited reason was a previous poor response to ovarian
stimulation (303 patients).
GnRH agonists were used approximately twice as
frequently as antagonists. The vast majority (95.5%) of
the GnRH-agonist cycles were performed using a long
protocol. The 2:1 formulation of follitropin alfa and
lutropin alfa was given throughout the whole ovarian
stimulation period in most cases (90.7% of cycles), and the
most commonly used daily dose of r-hLH (in over half of
the cycles) was 75 IU.
The use of the 2:1 formulation of follitropin alfa and
lutropin alfa for ovarian stimulation during routine ART
procedures was effective in achieving clinical pregnancies.
The overall clinical pregnancy rate observed in this study
Table III. Concomitant treatments received during assisted
reproductive technology cycles.
Treatment
Number of
cycles analysed Cycles n (%)
Contraceptive pill
(cycle programming)
885 283 (32.0)
GnRH antagonist 919 288 (31.3)
GnRH agonist 919 618 (67.2)
Long protocol 618 590 (95.5)
Intranasal administration 618 431 (69.7)
GnRH, gonadotrophin-releasing hormone.
Table IV. Number of fresh embryos transferred following ovarian
stimulation using the 2:1 formulation of follitropin alfa and
lutropin alfa.
Outcome Number of cycles analysed Cycles n (%)
Number of embryos
transferred:
1 741 129 (17.4)
2 741 466 (62.9)
3 741 146 (19.7)
652 K. Bu ¨hler & O. Naetherwas 27.5%. This is comparable with, albeit slightly lower
than, data from a recently published analysis of results
generated from European registers, in which the clinical
pregnancy rates for IVF and ICSI were 30.3% and 30.9%,
respectively [15]. The slightly lower pregnancy rate
reported in the current observational study may be a
reﬂection of the enrolled study population; almost 60%
of the patients were aged at least 35 years, and one-third
had previously experienced a poor response to ovarian
stimulation. Indeed, a pregnancy rate of 24.4% was
recently reported among women aged at least 35 years
who underwent IVF or ICSI in Germany [16].
The clinical pregnancy rate in this study was highest
among those who received a daily dose of 150 IU
r-hFSH:75 IU r-hLH (32.1% vs. 16.3% for those receiving
300 IU r-hFSH:150 IU r-hLH per day). However, it
should also be noted that women who were prescribed 300
IU r-hFSH:150 IU r-hLH per day were likely to have been
expected to have a poor response to ovarian stimulation.
In accordance with a previous report [10], the 2:1
formulation of follitropin alfa and lutropin alfa was found
to have a favourable safety proﬁle. Only three patients
developed OHSS (3/741, 0.4% of cycles resulting in
embryo transfer), of which only one required hospitaliza-
tion. Among the 60 pregnancies, there were 17 multiple
pregnancies, including one triplet pregnancy.
The nature of this observational, post-marketing surveil-
lance study must be acknowledged. Post-marketing sur-
veillance studies rely on accurate reporting of events. As
such, some data sets in this study are incomplete (and the
number of patients with evaluable data was different for
each outcome). Furthermore, due to the nature of the
questionnaire, there may be potential sources of variability
among responses submitted by different physicians.
For example, various deﬁnitions of a ‘poor response to
stimulation’ may have been used by individual physicians.
Although this was not a randomized, comparative study,
the RecDate database collects information from approxi-
mately 85% of all German IVF centres. Thus, the ﬁndings
of this observational study are considered to be reﬂective of
normal clinical ART practice in Germany, and offer a
valuable insight into the use of the 2:1 formulation of
follitropin alfa and lutropin alfa.
In conclusion, the interim results of this large observa-
tional study of the use of the 2:1 formulation of follitropin
alfa and lutropin alfa for ovarian stimulation (in 857
patients and 919 cycles of ART) show that it is associated
with a positive safety and effectiveness proﬁle in routine
clinical practice. The most commonly cited reasons for
prescribing the 2:1 formulation of follitropin alfa and
lutropin alfa were a low serum LH level and a previous
poor response to ovarian stimulation. Thus, the 2:1
formulation of follitropin alfa and lutropin alfa may be
beneﬁcial for women in either of these subgroups. The
study is currently ongoing, with the ﬁnal data expected to
be available in 2011.
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